glp-1 for ckd Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and RAs Frontiers | GLP-1 Receptor Agonists

10.1038/s41536-021-00140-4 211 TessemaB.SackU.KnigB.SerebrovskaZ.EgorovE

10.1371/journal.pone.0137429 329 MiyaokaT.KanayamaM.WakeR.HashiokaS.HayashidaM.NagahamaM.et al

Patients who suddenly increase exercise intensity or duration without adequate conditioning may experience delayed-onset muscle soreness (DOMS) or joint strain, which can be mistakenly attributed to the medication itself

For best results, apply once or twice daily for at least 90 days of consistent use

Firstly, the study was constrained by a relatively small number of participants, which could potentially impact the generalizability of the findings and its results should be interpreted with caution